Concepedia

A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan

Claire F. Verschraegen, Andrzej P. Kudelka, Wei Hu, Monique Vincent, John J. Kavanagh, Evelyne M. Loyer, Luc Bastien, Anil Duggal, Robert De Jager

Cancer Chemotherapy and Pharmacology · 2003 · 17 citations · 19 references

DOI

Concepts

References

19

Optimal two-stage designs for phase II clinical trials

Richard Simon · Controlled Clinical Trials · 1989 · 3.6K citations

, , +10

Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations

Kiyoshi Yamaoka, Terumichi Nakagawa, Toyozo Uno · Journal of Pharmacokinetics and Biopharmaceutics · 1978 · 2.1K citations

, , +11

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

Stephanie Green, Geoffrey R. Weiss · Investigational New Drugs · 1992 · 616 citations

, , +14

Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.

G.J.S. Rustin, Ann E. Nelstrop, Patrick McClean et al. · Journal of Clinical Oncology · 1996 · 380 citations

, , +15

Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.

Marc Maliepaard, Margôt A. van Gastelen, Akiko Tohgo et al. · PubMed · 2001 · 234 citations

, , +15